Therapy Areas: AIDS & HIV
Hikma Pharmaceuticals and Glenmark Specialty introduce RYALTRIS in US
31 August 2022 -

Hikma Pharmaceuticals PLC, a UK-based multinational pharmaceutical company, and Glenmark Specialty SA, a subsidiary of India-based Glenmark Pharmaceuticals Ltd., announced on Tuesday that they have launched RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US.

The US Food and Drug Administration (FDA) has approved the product intended to treat the symptoms of seasonal allergic rhinitis (SAR) in adult and paediatric patients 12 years of age and older.

Hikma said that this launch builds upon its position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US. RYALTRIS is claimed to be the only fixed-dose combination therapy that offers relief for the symptoms of SAR, both nasal and ocular in one nasal spray.



Related Headlines